BK and JC polyomaviruses and risk of urothelial bladder carcinoma: a preliminary study in the northern shores of Persian Gulf, Iran

Reza Taherkhani and Fatemeh Farshadpour*

Abstract

Background: Bladder cancer is a challenging public health concern in South of Iran because of its high prevalence and the related medical expenses. Although the exact etiology of bladder cancer remains unknown, given the cell transforming ability and oncolytic potential of the members of Polyomaviridae families, this study was conducted to evaluate the magnitude of BK polyomavirus (BKPyV) and John Cunningham polyomavirus (JCPyV) among patients with bladder cancer residents in the northern shores of the Persian Gulf, South of Iran.

Methods: Totally 211 patients with bladder cancer were enrolled in this study. Bladder biopsy samples of these patients and patients with interstitial cystitis as well as autopic samples of healthy bladder were tested for detection of BKPyV and JCPyV by semi-nested PCR-RFLP followed by sequencing.

Results: BKPyV and JCPyV were detected in 1.7% and 6.1% of bladder cancer samples, respectively. These samples were infected with JCPyV genotypes 2, 3 and 6 and BKPyV genotypes I and IV. BKPyV and JCPyV coinfection was detected in 2 samples. Moreover, one of the healthy bladder samples was positive for BKPyV, and one of the interstitial cystitis samples was positive for JCPyV. Although the majority of infected patients were in the age group 70–79 years, male, residents in Tangestan, stage Ta–T1, and low-grade and high-grade papillary urothelial carcinoma, the prevalence of BKPyV and JCPyV among patients with bladder cancer was not statistically associated with age, gender, place of residency, and stage and grade of the tumor.

Conclusion: Despite identifying BKPyV and JCPyV in a number of bladder cancer biopsy specimens and the high prevalence of bladder cancer among people resident in South of Iran, it is suggested that these viruses are unlikely to be effective causative factors in bladder carcinogenesis in this region. Therefore, environmental risk factors and genetic backgrounds may have a more prominent role than human polyomaviruses in the development of bladder cancer in South of Iran.

Keywords: Urothelial bladder carcinoma, Human polyomavirus, BK polyomavirus, John Cunningham polyomavirus, Prevalence, Genotype, Risk factors, Iran

Introduction

Bladder cancer, with approximately 570,000 new cases and an estimated 210,000 deaths annually, is considered to be the tenth most common cancer worldwide [1]. Over 90% of bladder cancers are transitional cell carcinoma, which are currently classified as urothelial bladder carcinoma, whereas 5% are squamous cell carcinoma and 2% are adenocarcinoma [1]. Cigarette smoking, prolonged...
use of antineoplastic drugs, arsenic in drinking water, occupational exposure to polycyclic hydrocarbons, aromatic amines and ionizing radiation, genetic background, chronic cystitis, schistosomiasis, and some bacterial and viral infections are possible risk factors for bladder cancer [2, 3]. Viral agents are responsible for 15–20% of all human cancers [2]. Among cancer-related viruses, BK polyomavirus (BKPyV) and John Cunningham polyomavirus (JCPyV) have been suggested as risk factors for the development of bladder cancer. This suggestion has been strengthened by the cell transforming ability and the oncogenic potential of some members of the Polyomaviridae family, including Merkel cell polyomavirus (MCPyV), SV40, Trichodysplasia spinulosa polyomavirus (TSPyV), JCPyV, BKPyV, HPyV6 and HPyV7 [4–6].

Human polyomaviruses are small, icosahedral, non-enveloped viruses in the family Polyomaviridae. Their circular double-stranded DNA genome contains an early coding region, which encodes two regulatory non-structural proteins (large and small tumor antigens), a late coding region, which encodes three structural proteins (VP1, VP2 and VP3) and a non-structural agnoprotein, and a non-coding region in between that regulates replication and transcription [7, 8]. These viruses might be transmitted through exposure to contaminated food, water and surfaces or via person-to-person contact, respiratory tract and organ transplantation [4]. Most people are exposed to these viruses in early childhood. Primary infection with these viruses during childhood results in life-long latent infection in peripheral-blood leukocytes, kidneys, urinary tract, lymphoid tissue, bone marrow and brain [7, 8]. Although the primary infection in immunocompetent individuals is usually asymptomatic or mild, in immunocompromised patients, infection with JCPyV is capable of causing progressive multifocal leukoencephalopathy, while infection with BKPyV can progress to hemorrhagic cystitis and nephropathies [4]. Moreover, the large tumor antigen (LTag) of BKPyV, JCPyV and SV40 might induce cell proliferation and downregulation of apoptosis by interacting with pRb and p53 tumor suppressor proteins, leading to cell transformation and tumorigenesis [5, 7].

Bladder cancer is a challenging public health concern in the South of Iran because of its high prevalence in this region and the related medical expenses. Age-standardized incidence rate (ASR) of bladder cancer is 19.00 per 100,000 in men and 6.83 per 100,000 in women in Bushehr province, South of Iran [9]. Although the exact etiology of bladder cancer remains unknown, given the cell transforming ability and the oncogenic potential of some members of Polyomaviridae families such as MCPyV, SV40, TSPyV, JCPyV and BKPyV, this study was conducted to evaluate the magnitude of BKPyV and JCPyV among patients with bladder cancer resident in the northern shores of the Persian Gulf, the South of Iran. In addition, the possible association between these infectious pathogens and the stage and grade of bladder cancer was evaluated. This is the first study on the molecular epidemiology of cancer-related viruses in this region. Information regarding the possible role of these viral agents in the development of bladder cancer might affect prevention and treatment strategies to reduce the incidence of bladder cancer.

Subjects and methods

Patients and sample collection

All of the patients with bladder cancer referred to the hospitals of Bushehr University of Medical Sciences located in southern Iran were included consecutively in this study. The patients were excluded from entering the study if they had a history of other malignancies or exhibited evidence of cancer metastasized to bladder tissue from another organ. Formalin-fixed paraffin-embedded bladder biopsy samples of 211 patients with bladder cancer and 11 patients with interstitial cystitis (non-cancerous) were collected from the archives of the pathology department of the hospitals. In addition, fresh frozen autopic samples of healthy bladder (non-neoplastic and non-cystitis) were taken from 19 deceased persons who died due to car accidents. All patients and the legal guardians of the deceased persons gave written informed consent to use their samples for viral detection and analysis. Grading and staging of tumors were carried out according to the World Health Organization/International Society of Urological Pathology (WHO/ISUP) and the American Joint Committee on Cancer/tumor, nodes, metastases (AJCC/TNM) staging system, respectively [1, 10, 11]. Demographic data and clinicopathologic characteristics were obtained from the medical record of the patients at the pathology department of the hospitals. This descriptive-analytical study was conducted with the approval of the Ethical Committee of the Bushehr University of Medical Sciences (Research project number: B-93-16-18) and funded by the Deputy Research and Affairs of the University (Grant Number: 8038). Besides, all methods were performed in accordance with the relevant guidelines and regulations.

DNA extraction

Ten-micrometer-thick tissue Sections (10 sections) were deparaffinized with 1 ml xylene (2 times), then wash with absolute ethanol (3 times) and 70% ethanol (1 time). DNA was extracted from the deparaffinized tissue samples and fresh frozen tissue samples using the High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer’s instructions. The
quantity and purity of the extracted DNA were evaluated by a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, Mass., USA), then the extracted DNA was aliquoted and stored at −70 °C until use. In order to confirm DNA integrity and to avoid false-negative results due to inappropriate DNA extraction or the presence of PCR inhibitors, a PCR assay was performed for all samples using specific primers for the human β-globin gene or the KRAS gene as the internal control [12, 13].

**PCR amplification and sequencing**
The detection of BKPyV and JCPyV was performed by semi-nested PCR-restriction fragment length polymorphism (PCR–RFLP) method, targeting the LTAg region of the genome. The 276 bp length fragment from the LTAg region was amplified in the first round PCR using outer primers AACGTCCTTAGGCTTCTACC (PEP-1F) and CAGRGATCTAAAGGTCTTAAGG (DP-R1). The second-round PCR was performed using inner primers AACGTCCTTAGGCTTCTACC (PEP-1F) and GGTGCCAACCTATGGAACAGA (PEP-R2) [14]. The amplified 176 bp length fragments from the second-round PCR were digested by BamHI restriction endonuclease to distinguish between BKPyV and JCPyV. In the case of JCPyV, the PCR amplicons were cleaved into 122 bp and 54 bp length fragments by BamHI, whereas in the case of BKPyV, no digestion occurred and the amplicons remained intact. The viral identity or the results of PCR–RFLP were also confirmed by sequencing. Moreover, the extracted DNA of positive samples was amplified by semi-nested PCR assay, which amplifies the VP1 regions of the BKPyV and JCPyV genome. The 562 bp and 433 bp length fragments from the VP1 region were amplified using outer primers [TGTAACGGCTAGCTAACCC (BKJC-f) and TCTGGGTACTTTGTYCTGTA (PoE2as)] and inner primers [GGAGAGTAGAAGGTCTTACCA (PoE1s) and TCTGGGTACTTTGTYCTGTA (PoE2as)], respectively [15]. The amplified 433 bp length fragment was sequenced by Sanger dideoxy sequencing technology to determine the genotypes of BKPyV and JCPyV (Macrogen Co., Korea). Known BKPyV and JCPyV positive clinical samples and PCR-grade water with PCR reagents were used as the positive and negative controls of the PCR assay, respectively. The sequences of primers, PCR conditions, and regions in the genome for detection of BKPyV and JCPyV are summarized in Table 1.

**Phylogenetic analysis**
The isolated sequences were aligned and compared with the reference sequences representing the standard genotypes of BKPyV and JCPyV available at the nucleotide database of the NCBI by the ClustalW program in the MEGA software version 7.0 (Biosdesign Institute, Tempe, AZ, USA). Then, the phylogenetic trees were constructed by the neighbor-joining methods.

**Statistical analysis**
Statistical analyses were performed using SPSS 17 package program (SPSS Inc., Chicago, IL, USA). Data were presented as mean ± standard deviation (SD), percentages, and frequencies. The Student’s t-test and the chi-square test or the Fisher exact test were used for data analysis, and P values < 0.05 were defined statistically significant.

| Virus          | Primers name | Sequences of primers 5′→3′ | Gene        | Region in genome | Annealing temperature (°C) | Size   | References |
|---------------|--------------|-----------------------------|-------------|------------------|-----------------------------|--------|------------|
| BKPyV and JCPyV | PEP-1F       | AAGCTTTAGGGCTTCTACC         | Large T antigen | 4497–4518       | 56                           | 276 bp | [14]       |
|               | DP-R1        | CAGRGATCTAAAGGTCTTAAGG      |             | 4764–4743        |                             |        |            |
|               | PEP-1F       | AAGCTTTAGGGCTTCTACC         |             | 4497–4518        | 56                           | 176 bp |            |
|               | PEP-R2       | GGTGCCAACCTATGGAACAGA       |             | 4673–4652        |                             |        |            |
| BKPyV and JCPyV | BKJC-f       | TGTACGGGGACTGTAACACC        | VP1         | 1629–1648        | 57                           | 562 bp | [15]       |
|               | PoE2as       | TCTGGGTACTTTGTYCTGTA        |             | 2191–2171        |                             |        |            |
|               | PoE1s        | GGAGAGTAGAAGGTCTTACCA       |             | 1758–1779        | 55                           | 433 bp |            |
|               | PoE2as       | TCTGGGTACTTTGTYCTGTA        |             | 2191–2171        |                             |        |            |
| Internal controls | PCO3F         | ACAACACTGTTGCTCAGGC         | β globin    | 5,248,179        | 55                           | 110 bp | [12]       |
|               | PCO4R        | CAACTTGTCCAGTCTCC          |             | 5,248,288        |                             |        |            |
|               | KRAS-F       | GGTGGTTGTTATATAAGGTTACTCGA | KRAS        | 10,423           | 55                           | 263 bp | [13]       |
|               | KRAS-R       | TCCTGCACCTAAATATGCA         |             |                  |                             |        |            |
Results

Information of 211 patients with bladder cancer was available at the archives of the pathology department of the hospitals located in southern Iran. Of these, 74 patients were from Bushehr, 34 patients were from Tangestan, 44 patients were from Dashtestan, 27 patients were from Dashti, 13 patients were from Dayer, 3 patients were from Deylam, 5 patients were from Kangar, 10 patients were from Genaveh, and 1 patient was from Jam city. The mean age ± SD of patients with bladder cancer was 64.52 ± 13.78 years with a range of 27–92 years. The majority of patients were in the age group 50–69 years (48.34%), male (76.8%), residents in Bushehr city (35.1%), and had low-grade papillary urothelial carcinoma (39.8%) and were in stage Ta–T1 (89.1%) (Table 2). Patients in stage T2–T3 (71.57 ± 13.15) had a higher mean age compared to patients in stage Ta–T1 (63.23 ± 13.94). Moreover, patients with high-grade papillary urothelial carcinoma (71.1 ± 11.68) had a higher mean age compared to patients with urothelial papilloma (50.0 ± 7.26). Overall, the mean age of patients increased with increasing the stage and grade of cancer.

Of 211 patients with bladder cancer, 30 patients were excluded due to the absence of formalin-fixed paraffin-embedded bladder biopsy samples or poor tissue quality following DNA extraction. Overall, 181 cancerous bladder samples and 30 non-cancerous bladder samples were tested for detection of BKPyV and JCPyV. These 30 non-cancerous samples included 11 interstitial cystitis and 19 healthy bladder samples, and were taken from 16 men and 14 women, ages ranging from 22 to 84 years (58.0 ± 18.78). Of these, 18 samples were from Bushehr city, 5 samples were from Dashtestan, 2 samples were from Genaveh, 3 samples were from Tangestan, and 2 samples were from Dashti. BKPyV and JCPyV were detected in 1.7% (3/181) and 6.1% (11/181) of the bladder cancer samples, respectively. One of the healthy bladder samples was positive for BKPyV, and one of

| Table 2 | Demographic data and tumor characteristics of patients with bladder cancer in the South of Iran |

| Age groups (years) | No. of all patients (%) | No. of formalin-fixed paraffin-embedded bladder cancer biopsy samples (%) |
|-------------------|-------------------------|---------------------------------------------------------------------|
| 27–39             | 9 (4.3)                 | 7 (3.9)                                                             |
| 40–49             | 21 (10.0)               | 15 (8.3)                                                            |
| 50–59             | 50 (23.7)               | 46 (25.4)                                                           |
| 60–69             | 52 (24.6)               | 45 (24.9)                                                           |
| 70–79             | 46 (21.8)               | 39 (21.5)                                                           |
| ≥ 80              | 33 (15.6)               | 29 (16.0)                                                           |

| Gender | No. of all patients (%) | No. of formalin-fixed paraffin-embedded bladder cancer biopsy samples (%) |
|--------|-------------------------|---------------------------------------------------------------------|
| Male   | 162 (76.8)              | 138 (76.2)                                                          |
| Female | 49 (23.2)               | 43 (23.8)                                                           |

| Place of residence (city) | No. of all patients (%) | No. of formalin-fixed paraffin-embedded bladder cancer biopsy samples (%) |
|---------------------------|-------------------------|---------------------------------------------------------------------|
| Bushehr                   | 74 (35.1)               | 63 (34.8)                                                          |
| Tangestan                 | 34 (16.1)               | 27 (14.9)                                                          |
| Dashtestan                | 44 (20.9)               | 38 (21.0)                                                          |
| Dashti                    | 27 (12.8)               | 25 (13.8)                                                          |
| Dayer                     | 13 (6.2)                | 11 (6.1)                                                           |
| Deylam                    | 3 (1.4)                 | 3 (1.7)                                                            |
| Kangar                    | 5 (2.4)                 | 5 (2.8)                                                            |
| Genaveh                   | 10 (4.7)                | 8 (4.4)                                                            |
| Jam                       | 1 (0.5)                 | 1 (0.6)                                                            |

| Stage of tumor | No. of all patients (%) | No. of formalin-fixed paraffin-embedded bladder cancer biopsy samples (%) |
|----------------|-------------------------|---------------------------------------------------------------------|
| Ta–T1          | 188 (89.1)              | 166 (91.7)                                                          |
| T2–T3          | 23 (10.9)               | 15 (8.3)                                                            |

| Grade of tumor | No. of all patients (%) | No. of formalin-fixed paraffin-embedded bladder cancer biopsy samples (%) |
|----------------|-------------------------|---------------------------------------------------------------------|
| Urothelial papilloma | 4 (1.9)               | 4 (2.2)                                                            |
| Papillary urothelial neoplasms of low malignant | 66 (31.3) | 62 (34.3) |
| Low-grade papillary urothelial carcinoma | 84 (39.8) | 68 (37.6) |
| High-grade papillary urothelial carcinoma | 57 (27.0) | 47 (26.0) |
the interstitial cystitis samples was positive for JCPyV (Figs. 1, 2 and 3). These samples were infected with JCPyV genotypes 2 (two samples), 3 (nine samples) and 6 (one sample) and BKPyV genotypes I (two samples) and IV (two samples) (Figs. 4, 5 and 6). The internal control was positive in all samples.

The BKPyV positive patients were in the age group 70 to ≥80 years, male, residents in Tangestan and Dashti and had papillary urothelial neoplasms of low malignant,
Fig. 3 Electrophoresis of PCR products of VP1 region of BK polyomavirus (BKPyV) and John Cunningham polyomavirus (JCPyV) genome extracted from bladder tissue samples on 2% agarose gel. L, 100-bp DNA ladder; N, negative control; P, positive control; 1, 2, 3, 4, 5 and 6, amplified products (~433 bp).

Discussion

Bladder cancer is the 9th leading cause of cancer-related deaths worldwide, causing nearly 210,000 deaths each year [1]. Among possible risk factors for bladder cancer, infectious pathogens are of particular interest for their carcinogenesis properties. Since infectious agent-related cancers can be predictable and preventable by screening and vaccination programs [16]. However, to achieve this goal, the role of infectious pathogens in the development of specific cancers should be confirmed. Therefore, this study was performed to detect BKPyV and JCPyV in bladder cancer tissues and to screening for the presence of these viral pathogens among patients with bladder cancer. In this study, BKPyV and JCPyV were detected in 1.7% and 6.1% of the bladder cancer biopsy specimens, respectively.

The association between human polyomaviruses and bladder carcinoma continues to be controversial. While some studies suggested an association between BKPyV and JCPyV infections and bladder carcinoma [17–19], the other studies denied this association [3, 20–22]. These studies have been performed in different populations with different environmental risk factors and genetic backgrounds and have failed to reach a consensus. A recent study proposed the role of BKPyV in the development of bladder cancer via the anti-viral apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC)-mediated damage of the urothelial genome. In this hit-and-run mode of carcinogenesis, despite inducing APOBEC3B expression by LTAg of BKPyV, the causative viral agent is absent in the tumoral tissue probably due to immune clearance of BKPyV [23]. The present study, despite identifying BKPyV and JCPyV in a number of bladder cancer biopsy specimens in the South of Iran, suggests that these viruses are unlikely to be effective causative factors in bladder cancer in this region. Nevertheless, prospective cohort studies are needed to reach a more definite conclusion and to achieve further understanding of the association between BKPyV and JCPyV infections and the development of bladder cancer in an Iranian population.

The prevalence of 1.7% for BKPyV observed in this study is higher than that reported among patients with bladder cancer in Hungary (0.0%) [22] but lower than those reported in the United Kingdom (3.33%) [3], the United States (5.5%) [21], Mashhad (North-East of Iran) (13.7%) [24] and Italy (55%) [17]. Moreover, the prevalence of 6.1% for JCPyV observed in this study is higher than that reported among patients with bladder cancer in the United Kingdom (0.87%) [3] but lower than that reported in Italy (25%) [17]. These variations in the prevalence of human polyomaviruses in these studies could be due to differences in the type of specimen, processing methods, the sensitivity of the detection assays, and sociodemographic characteristics of the study population.

In this study, multiple samples from different parts of the tumoral tissue were tested for each patient. Since BKPyV and JCPyV may not infect all cancerous parts equally, testing the samples outside the infected site can lead to false-negative results. In addition, a nested PCR method was used to detect BKPyV and JCPyV in bladder tissue specimens. Due to the low number of copies of viral DNA in tissue specimens, a nested PCR assay is more useful for the detection of BKPyV and JCPyV than...
conventional PCR assays. So that all positive samples were identified in the second round of PCR. However, the risk of contamination, which leads to false-positive results, is higher in nested PCR assay than in one-step PCR assay [25]. In this study, to avoid contamination during PCR procedures, strict quality controls were applied. Moreover, positive and negative controls were used to ensure the accuracy of the results. Accidental
Fig. 5 Neighbor-joining phylogenetic tree based on ~433 bp nucleotide sequence of the VP1 region of JCPyV isolates from the bladder tissue samples of patients in the South of Iran (blue mark). Bootstrap re-sampling strategy and reconstruction were carried out 1000 times to confirm the reliability of the phylogenetic tree.
contamination at the time of sample processing, which can lead to false-positive results, is another issue. During sectioning each sample, the necessary precautions were taken to avoid cross-contamination with the next sample. In this study, the prevalence of BKPyV and JCPyV among patients with bladder cancer was not statistically associated with age, gender, place of residency, and the stage and grade of bladder cancer, although the majority of infected patients were in the age group 70–79 years, male, residents in Tangestan, stage Ta-T1, and low-grade and high-grade papillary urothelial carcinoma. Similarly, a study from the United Kingdom reported no association between the prevalence of BKPyV and JCPyV and stage and grade of the tumor [3]. Bladder cancer commonly affects older ages, with a peak incidence in the 7th and 8th decades of life, and is more common in men [17]. In this study, the mean age of patients increased with increasing the stage and grade of bladder cancer. So that patients in stage T2–T3 had a higher mean age compared to patients in stage Ta–T1. Moreover, patients with high-grade papillary urothelial carcinoma had a higher mean age compared to patients with urothelial papilloma.

Based on the nucleotide sequence analysis of the VP1 region, the BKPyV genotypes I and IV and the JCPyV genotypes 2, 3 and 6 were found among patients with bladder cancer in this study. Currently, 4 BKPyV genotypes (I, II, III, and IV) with 4 subtypes related to genotype I (Ia, Ib-1, Ib-2 and Ic) and six subtypes related to genotype IV (IVa-1, IVa-2, IVb-1, IVb-2, IVc-1 and IVc-2), and 8 JCPyV genotypes (1–8) with 5 subtypes related to genotype 2 (2a, 2b, 2c, 2d and 2e) have been identified depending on the geographical distribution [7, 26]. The BKPyV genotype I shows a widespread distribution and is prevalent in different parts of the world. The BKPyV genotype IV is predominant in Asia. The BKPyV genotypes II and III are less prevalent and are almost rare [27, 28]. The JCV genotypes 1 and 4 are predominant in the United States and Europe. The JCV genotypes 2 and 7 are prevalent in Asia. The JCV genotypes 3 and 6 are the main genotype in Africa. The JCV genotype 5 is a recombination of genotypes 2b and 6. The JCV genotype 8 has been isolated from Papua New Guinea and Western Pacific populations [26].

We have carried out the largest screening of BKPyV and JCPyV to date in an Iranian population with bladder cancer, finding that these viruses are unlikely to be effective causative factors in bladder carcinogenesis among patients with bladder cancer resident in the northern shores of the Persian Gulf. In addition, data on BKPyV and JCPyV infections in bladder cancer, including distribution by age, gender, place of residency, tumor grade and tumor stage, were analyzed.
Besides, the high number of screened samples increases the generalizability of the results to the population resident in this region. In addition, this study highlighted the importance of testing multiple samples from different parts of the tumoral tissue for each patient. In this study, due to the limited number of non-cancerous bladder samples in the archives of the pathology department of the hospitals and difficulties in acquiring healthy bladder samples, only 30 non-cancerous samples were screened for detection of BKPyV and JCPyV. The low number of control patients is one of the limitations of this study. As another limitation, paraffin-embedded tissue samples were used to detect BKPyV and JCPyV. The detection rate of viral DNA might be slightly higher in fresh frozen tissue samples compared to paraffin-embedded tissue samples.

**Conclusion**

According to the results of the present study, despite identifying BKPyV and JCPyV in a number of bladder cancer biopsy specimens and the high prevalence of bladder cancer among people resident in the South of Iran, it is suggested that these viruses are unlikely to be effective causative factors in bladder carcinogenesis in this region. However, alternative molecular techniques such as RNA-ISH, FISH, and IHC should be used in order to exclude the potential role of these two viruses in promoting bladder cancer. Moreover, our results showed no significant association between the prevalence of BKPyV and JCPyV and age, gender, place of residency, tumor grade and tumor stage. Therefore, environmental risk factors and genetic backgrounds may have a more prominent role than human polyomaviruses in the development of bladder cancer. Nevertheless, further studies are required to investigate these

| Age groups (years)  | No. of all participants (%) | No. of BKPyV positive subjects (%) | No. of BKPyV negative subjects (%) | P-Value |
|---------------------|-----------------------------|------------------------------------|------------------------------------|---------|
| 27–39               | 7 (3.9)                     | 0 (0.0)                            | 7 (3.9)                            | 0.374   |
| 40–49               | 15 (8.3)                    | 0 (0.0)                            | 15 (8.4)                           |         |
| 50–59               | 46 (25.4)                   | 0 (0.0)                            | 46 (25.8)                          |         |
| 60–69               | 45 (24.9)                   | 0 (0.0)                            | 45 (25.3)                          |         |
| 70–79               | 39 (21.5)                   | 2 (66.7)                           | 37 (20.8)                          |         |
| ≥ 80                | 29 (16.0)                   | 1 (33.3)                           | 28 (15.7)                          |         |

**Gender**

| Gender    | No. of all participants (%) | No. of BKPyV positive subjects (%) | No. of BKPyV negative subjects (%) | P-Value |
|-----------|-----------------------------|------------------------------------|------------------------------------|---------|
| Male      | 138 (76.2)                  | 3 (100.0)                          | 135 (75.8)                         | 0.330   |
| Female    | 43 (23.8)                   | 0 (0.0)                            | 43 (24.2)                          |         |

**Place of residence (city)**

| Place of residence (city) | No. of all participants (%) | No. of BKPyV positive subjects (%) | No. of BKPyV negative subjects (%) | P-Value |
|---------------------------|-----------------------------|------------------------------------|------------------------------------|---------|
| Bushehr                   | 63 (34.8)                   | 0 (0.0)                            | 63 (35.4)                          |         |
| Tangestan                 | 27 (14.9)                   | 2 (66.7)                           | 25 (14.0)                          |         |
| Dashtestan                | 38 (21.0)                   | 0 (0.0)                            | 38 (21.3)                          |         |
| Daskht                   | 25 (13.8)                   | 1 (33.3)                           | 24 (13.5)                          |         |
| Dayer                     | 11 (6.1)                    | 0 (0.0)                            | 11 (6.2)                           |         |
| Deyleam                   | 3 (1.7)                     | 0 (0.0)                            | 3 (1.7)                            |         |
| Kangan                    | 5 (2.8)                     | 0 (0.0)                            | 5 (2.8)                            |         |
| Genaveh                   | 8 (4.4)                     | 0 (0.0)                            | 8 (4.5)                            |         |
| Jam                       | 1 (0.6)                     | 0 (0.0)                            | 1 (0.6)                            |         |

**Stage of tumor**

| Stage of tumor          | No. of all participants (%) | No. of BKPyV positive subjects (%) | No. of BKPyV negative subjects (%) | P-Value |
|-------------------------|-----------------------------|------------------------------------|------------------------------------|---------|
| Ta–T1                   | 166 (91.7)                  | 3 (100.0)                          | 163 (91.6)                         | 0.600   |
| T2–T3                   | 15 (8.3)                    | 0 (0.0)                            | 15 (8.4)                           |         |

**Grade of tumor**

| Grade of tumor                      | No. of all participants (%) | No. of BKPyV positive subjects (%) | No. of BKPyV negative subjects (%) | P-Value |
|-------------------------------------|-----------------------------|------------------------------------|------------------------------------|---------|
| Urothelial papilloma                | 4 (2.2)                     | 0 (0.0)                            | 4 (2.2)                            | 0.986   |
| Papillary urothelial neoplasms of low malignant | 62 (34.3)                   | 1 (33.3)                           | 61 (34.3)                          |         |
| Low-grade papillary urothelial carcinoma | 68 (37.6)                   | 1 (33.3)                           | 67 (37.6)                          |         |
| High-grade papillary urothelial carcinoma | 47 (26.0)                   | 1 (33.3)                           | 46 (25.8)                          |         |
Table 4 Prevalence of John Cunningham polyomavirus (JCPyV) according to socio-demographic data and tumor characteristics among patients with bladder cancer in the South of Iran

| Age groups (years) | No. of all participants (%) | No. of JCPyV positive subjects (%) | No. of JCPyV negative subjects (%) | Adjusted OR (95% CI) | P-Value |
|--------------------|-----------------------------|-----------------------------------|-----------------------------------|----------------------|---------|
| 27–39              | 7 (3.9)                     | 2 (18.2)                          | 5 (2.9)                           | 1.0                  |         |
| 40–49              | 15 (8.3)                    | 1 (9.1)                           | 14 (8.2)                          | 5.600 (0.412–76.049) | 0.196   |
| 50–59              | 46 (25.4)                   | 0 (0.0)                           | 46 (27.1)                         | 0.000                | 0.997   |
| 60–69              | 45 (24.9)                   | 2 (18.2)                          | 43 (25.3)                         | 6.600 (0.984–75.151) | 0.052   |
| 70–79              | 39 (21.5)                   | 6 (54.5)                          | 33 (19.4)                         | 2.200 (0.344–14.079) | 0.405   |
| ≥ 80               | 29 (16.0)                   | 0 (0.0)                           | 29 (17.1)                         | 0.000                | 0.998   |

| Gender             | No. of all participants (%) | No. of JCPyV positive subjects (%) | No. of JCPyV negative subjects (%) | Adjusted OR (95% CI) | P-Value |
|--------------------|-----------------------------|-----------------------------------|-----------------------------------|----------------------|---------|
| Male               | 138 (76.2)                  | 9 (81.8)                          | 129 (75.9)                        | 1.0                  |         |
| Female             | 43 (23.8)                   | 2 (18.2)                          | 41 (24.1)                         | 1.430 (0.297–6.888)  | 0.655   |

| Place of residence (city) | No. of all participants (%) | No. of JCPyV positive subjects (%) | No. of JCPyV negative subjects (%) | Adjusted OR (95% CI) | P-Value |
|--------------------------|-----------------------------|-----------------------------------|-----------------------------------|----------------------|---------|
| Bushehr                  | 63 (34.8)                   | 2 (18.2)                          | 61 (35.9)                         | 1.0                  |         |
| Tangestan                | 27 (14.9)                   | 4 (36.4)                          | 23 (13.5)                         | 0.189 (0.032–1.100)  | 0.064   |
| Dashtestan               | 38 (21.0)                   | 1 (9.1)                           | 37 (21.8)                         | 1.213 (0.106–13.848) | 0.876   |
| Dashti                   | 25 (13.8)                   | 1 (9.1)                           | 24 (14.1)                         | 0.787 (0.068–9.087)  | 0.848   |
| Dayer                    | 11 (6.1)                    | 1 (9.1)                           | 10 (5.9)                          | 0.328 (0.027–3.962)  | 0.380   |
| Deylam                   | 3 (1.7)                     | 1 (9.1)                           | 2 (1.2)                           | 0.066 (0.004–1.06)   | 0.055   |
| Kangan                   | 5 (2.8)                     | 0 (0.0)                           | 5 (2.9)                           | 0.000                | 0.999   |
| Genaveh                  | 8 (4.4)                     | 1 (9.1)                           | 7 (4.1)                           | 0.230 (0.018–2.866)  | 0.253   |
| Jam                      | 1 (0.6)                     | 0 (0.0)                           | 1 (0.6)                           | 0.000                | 1.000   |

| Stage of tumor | No. of all participants (%) | No. of JCPyV positive subjects (%) | No. of JCPyV negative subjects (%) | Adjusted OR (95% CI) | P-Value |
|----------------|-----------------------------|-----------------------------------|-----------------------------------|----------------------|---------|
| Ta–T1          | 166 (91.7)                  | 10 (90.9)                         | 156 (91.8)                        | 1.0                  |         |
| T2–T3          | 15 (8.3)                    | 1 (9.1)                           | 14 (8.2)                          | 0.897 (0.107–7.530)  | 0.921   |

| Grade of tumor | No. of all participants (%) | No. of JCPyV positive subjects (%) | No. of JCPyV negative subjects (%) | Adjusted OR (95% CI) | P-Value |
|----------------|-----------------------------|-----------------------------------|-----------------------------------|----------------------|---------|
| Urothelial papilloma | 4 (2.2)                     | 0 (0.0)                           | 4 (2.4)                           | 1.0                  |         |
| Papillary urothelial neoplasms of low malignant | 62 (34.3)                  | 3 (27.3)                          | 59 (34.7)                         | 0.000                | 0.999   |
| Low-grade papillary urothelial carcinoma | 68 (37.6)                  | 4 (36.4)                          | 64 (37.6)                         | 0.000                | 0.999   |
| High-grade papillary urothelial carcinoma | 47 (26.0)                  | 4 (36.4)                          | 43 (25.3)                         | 0.000                | 0.999   |

factors and their associations with bladder carcinoma in the South of Iran.

Acknowledgements
The authors would like to acknowledge grant no. 8038 supported by the Deputy Research and Affairs of the Bushehr University of Medical Sciences, Bushehr, Iran.

Author contributions
FF and TR designed and performed the study. TR drafted and edited the manuscript. Both authors read and approved the final draft of the manuscript.

Funding
This study was funded by Bushehr University of Medical Sciences with grant number 8038.

Availability of data and materials
All relevant data are within the paper.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethical Committee of Bushehr University of Medical Sciences with reference number B-93-16-18. All patients and the legal guardians of the deceased persons gave written informed consent to use their bladder tissue samples for viral detection. All methods were performed under the relevant guidelines and regulations.

Consent for publication
The patients and the legal guardians of the deceased persons gave written informed consent to publish their data in a journal article.

Competing interests
The authors declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

Received: 22 May 2022   Accepted: 14 September 2022
Published online: 19 September 2022
References
1. Bogen JP, Grzeschik J, Jakobsen J, Bahre A, Hock B, Kolmar H. Treating bladder cancer: engineering of current and next generation antibody- fusion protein-, miRNA- Cell- and viral-based Therapeutics Front Oncol. 2021;11:672626. https://doi.org/10.3389/fonc.2021.672626.
2. Khatri A, Salavatia Z, Razi zadeh MH. Bladder cancer and human papillomavirus association: a systematic review and meta-analysis. Infect Agent Cancer. 2022;17(1):3. https://doi.org/10.1186/s13027-022-00415-5.
3. Llewellyn MA, Gordon NS, Abbotts B, James ND, Zeegers MP, Cheng KK, et al. Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Sci Rep. 2018;8(1):11290. https://doi.org/10.1038/s41598-018-29438-y.
4. Prado JCM, Monezi TA, Amorim AT, Lino V, Paladino A, Boccardo E. Human polyomaviruses and cancer: an overview. Clinics. 2018;73(suppl 1):e558s. https://doi.org/10.6061/clinics/2018/e558s.
5. Delbue S, Comar M, Ferrante P. Review on the relationship between human polyomaviruses-associated tumors and host immune system. Clin Dev Immunol. 2012;2012:542092.
6. Klufah F, Mobaraki G, Liu D, Alharbi RA, Kurz AK, Speel EJM, et al. Emerging role of human polyomaviruses 6 and 7 in human cancers. Infect Agent Cancer. 2021;16(1):35. https://doi.org/10.1186/s13027-021-00374-3.
7. Furmaga J, Kowalczyk M, Zapolski T, Furmaga O, Krakowski L, Rudzki G, et al. BK Polyomavirus-Biology. Genom Var Diag Viruses. 2018;13(1):1–17. https://doi.org/10.3390/v13081502.
8. Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK polyomavirus nephropathy in kidney transplantation: balancing rejection and infection. Viruses. 2021;13(3):487. https://doi.org/10.3390/v13030487.
9. Nowrooz MR, Amini E, Farkhani EM, Nowrooz A, Ayati M, Reza zadeh S, et al. National and subnational incidence of bladder cancer in Iran: results of the Iranian National Population-Based Cancer Registry Over A 12-Year Period. 2021.
10. Pan C-C, Chang Y-H. The 2004 World Health Organization/International Society of Urological Pathology classification system for non-muscle invasive bladder cancer. Urol Sci. 2013;3(24):96–100.
11. Park JH, Moon IC. Tumor, nodes, metastases (TNM) classification system. Int J Cancer. 2007;120(6):1248–51. https://doi.org/10.1002/ijc.22494.
12. Taherkhani R, Farshadpour F, Makvandi M, Mombeini H, Haghighi SB, Dastoorpoor M, Khodadad N, Babaahmadi Mk, et al. Molecular epidemiology of JC polyomavirus in HIV-infected patients and healthy individuals from Iran. Braz J Microbiol. 2020;51(1):37–43. https://doi.org/10.1016/j.bjm.2019.09.017.
13. Karim Dehshesmele M, Makvandi M, Timori A. Prevalence of human polyomavirus JC and BK in normal population. Asian Pac J Cancer Prev. 2020;21(10):2877–82. https://doi.org/10.3355/APJCP.2020.21.10.2877.
14. Arthur RR, Dagostin S, Shah KV. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol. 1989;27(6):1174–9.
15. Chehadeh W, Kunen SS, Nampa copy MR. Molecular characterization of BK and JC viruses circulating among potential kidney donors in Kuwait. Int J Med Sci. 2013;10:683464. https://doi.org/10.1155/2013/683464.
16. Visalli G, Faccioli A, d’Aleao F, Pinzone M, Condorelli F, Picerno I, et al. HPV and urinary bladder carcinoma: a review of the literature. World Cancer Res J. 2018;5(1):e1038.
17. Fioriti D, Pietropaolo V, Dal Forno S, Laurenti C, Chiariini F, Degener AM. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. Int J Immunopathol Pharmacol. 2005;16(3):285–8. https://doi.org/10.1177/03995270030301600.
18. Wu SW, Liou JH, Yeh KT, Hung TW, Chang HR. The prevalence and prognostic significance of polyomavirus infection in patients with urothelial carcinoma of the bladder. Urol J. 2016;13(4):2773–8.
19. Zeng Y, Sun J, Bao J, Zhu T. BK polyomavirus infection promotes growth and aggressiveness in bladder cancer. Virol J. 2020;17(1):139. https://doi.org/10.1186/s12985-020-01399-7.
20. Polesel J, Ghe t T, Talamini R, Shahzad N, Lenardon O, Syl la B, et al. Urinary human papillomavirus and polyomavirus infection and bladder cancer risk. Br J Cancer. 2012;106(1):222–6. https://doi.org/10.1038/bjc.2011.519.
21. Rollison DE, Sexton WJ, Rodriguez AR, Kang LC, Daniel R, Shah KV. Lack of BK virus DNA sequences in most transitional-cell carcinomas of the blad der. Int J Cancer. 2007;120(6):1248–51. https://doi.org/10.1002/ijc.22494.
22. Cismon E, Bidiga L, Mehes G, Gergely L. No evidence of human polyoma virus 9, WU and KI DNA in kidney and urinary bladder tumour tissue samples. Pathobiology J Immunopathol Mol Cell Biol. 2016;83(5):252–7. https://doi.org/10.1159/000445120.
23. Baker SC, Mason AS, Slip RG, Skinner KT, Macdonald A, Masood O, et al. Induction of AP0BEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKV) as a hit-and-run driver for bladder cancer. Oncogene. 2022;41(15):2139–51.
24. Javadzadeh T, Gharib M, Khadem-Rezayant, Meshkat Z, Amel-Jamehdr S, Kalantari M-R, et al. Frequency of BK polyomavirus in bladder cancer. Iran J Virol. 2020;14(1):6–11.
25. Taherkhani R, Farshadpour F. Molecular identification and clinical characteristics of mumps virus and human herpesviruses associated with aseptic meningitis in South of Iran. Viruses. 2021;32(4):666–73. https://doi.org/10.3390/v13030021-00718-y.
26. Makvandi M, Mombeini H, Haghighi SB, Dastoorpoor M, Khodadad N, Babaahmadi Mk, et al. Molecular epidemiology of JC polyomavirus in HIV-infected patients and healthy individuals from Iran. Braz J Microbiol. 2020;51(1):37–43. https://doi.org/10.1016/j.bjm.2019.09.017.
27. Karim Dehshesmele M, Makvandi M, Timori A. Prevalence of human polyomavirus JC and BK in normal population. Asian Pac J Cancer Prev. 2020;21(10):2877–82. https://doi.org/10.3355/APJCP.2020.21.10.2877.
28. Safaei F, Mehoebbi A, Hassanpour M, Nikoo HR, Tabaraeei A. Viru s of human BK virus and John Cunningham virus among renal transplant recipients and healthy control in Southeast of Caspian Sea. Intervirology. 2021;64(3):111–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions